Scholarlink

<p>Despite improvements in surgical techniques, advances in delivery of radiation therapy, and development of therapies with central nervous system (CNS) activity, the presence of CNS metastases from breast cancer is frequently associated with a poor prognosis. In 2023, the leadership of the Breast International Group and National Cancer Institute’s National Clinical Trials Network convened a CNS working group to identify key challenges and discuss ways that international collaborations could push forward progress in the field. This review reflects initial discussions of the working group and addresses (1) the possible role of screening for CNS metastases, (2) optimal sequencing of local and systemic therapies among patients with human epidermal growth factor receptor 2 (HER2)-positive CNS metastases, (3) management of leptomeningeal disease, and (4) the importance of developing innovative clinical trials for treatment and prevention of CNS metastases across breast cancer subtypes that is informed by preclinical data/basic science, with seamless knowledge translation to allow for rapid clinical adoption.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Novel treatment strategies and key research priorities for patients with breast cancer and central nervous system (CNS) metastases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月20日

查看全文
  • Katarzyna J. Jerzak,
  • Evangelia D. Razis,
  • Elisa Agostinetto,
  • Priscilla K. Brastianos,
  • Margaret E. Gatti-Mays,
  • Manmeet S. Ahluwalia,
  • Carey Anders,
  • Rupert Bartsch,
  • Fatima Cardoso,
  • Elisabeth G. E. de Vries,
  • Sarra El-Abed,
  • Barbro Linderholm,
  • Ciara C. O’Sullivan,
  • Arjun Sahgal,
  • Sarah Sammons,
  • Patricia A. Spears,
  • Eva Schumacher-Wulf,
  • Carlo Palmieri,
  • Nancy U. Lin

摘要

Despite improvements in surgical techniques, advances in delivery of radiation therapy, and development of therapies with central nervous system (CNS) activity, the presence of CNS metastases from breast cancer is frequently associated with a poor prognosis. In 2023, the leadership of the Breast International Group and National Cancer Institute’s National Clinical Trials Network convened a CNS working group to identify key challenges and discuss ways that international collaborations could push forward progress in the field. This review reflects initial discussions of the working group and addresses (1) the possible role of screening for CNS metastases, (2) optimal sequencing of local and systemic therapies among patients with human epidermal growth factor receptor 2 (HER2)-positive CNS metastases, (3) management of leptomeningeal disease, and (4) the importance of developing innovative clinical trials for treatment and prevention of CNS metastases across breast cancer subtypes that is informed by preclinical data/basic science, with seamless knowledge translation to allow for rapid clinical adoption.